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Dear Editor,
The number of clinical studies on the 
effects of thyroid function on fertility and 
pregnancy is increasing rapidly. However, 
there are still unanswered clinically impor-
tant questions such as whether women 
with mild thyroid function test abnor-
malities or thyroid peroxidase antibody 
(TPOAb) positivity prior to conception or 
during pregnancy can benefit from levo-
thyroxine treatment. While various ran-
domized trials have been performed, these 
have not always been able to either include 
the most up-to-date definition of thyroid 
function test abnormalities, to investigate 
currently recognized high-risk subgroups, 
or to translate recent insights from human 
physiology and observational studies into 
study designs [1, 2]. In an effort to over-
come such limitations, we have now ex-
tended the Consortium on Thyroid and 
Pregnancy to include randomized trials 
with the aim to combine data and perform 
individual participant data meta-analyses.
The initial aim of the Consortium on 
Thyroid and Pregnancy was to create a for-
mal platform for collaboration that can fa-
cilitate high-quality studies on the clinical 
consequences of thyroid function test 
abnormalities or thyroid autoimmunity 
on fertility, pregnancy, or child outcomes. 
Currently, the consortium consists of 23 
prospective cohort studies with data on 
close to 100,000 mother-and-child pairs. 
We have recently published our first study 
[3], and five other studies are currently on-
going (see http://www.consortiumthyroid-
pregnancy.org).
Through this letter, we would like to in-
vite anyone who has observational data 
available (published or unpublished) to 
join the pre-existing Consortium on Thy-
roid and Pregnancy and join currently on-
going studies. Furthermore, we would like 
to invite anyone with data available from 
randomized trials (published or unpub-
lished) to join the new randomized trial 
arm of the Consortium on Thyroid and 
Pregnancy for the setup of new studies to 
further add to knowledge gaps in this field 
of research. At the bottom of this letter, the 
inclusion criteria for various types of data 
that can contribute to the Consortium on 
Thyroid and Pregnancy can be found. We 
hope you can join our efforts to advance 
evidence-based medicine in the field of 
thyroid, fertility, and pregnancy within the 
Consortium on Thyroid and Pregnancy.
If you wish to participate, or require 
more information, please contact us via e-
mail.
Inclusion Criteria
For population-based cohorts for stud-
ies on thyroid outcomes:
• Non-selected or population-based pro-
spective cohorts
• Serum TSH or FT4 or thyroid antibod-
ies measured in pregnant women (any 
gestational age)
• Disease-specific prospective cohorts 
can be included for specific studies 
when deemed relevant
• Data on thyroid medication usage to 
identify potential bias
For population-based cohorts for stud-
ies on pregnancy or child outcome:
• Non-selected or population-based pro-
spective cohorts
• Serum TSH or FT4 or thyroid antibod-
ies measured in pregnant women (any 
gestational age)
• Follow-up complete until the end of 
pregnancy or beyond
• Disease-specific prospective cohorts 
can be included for specific studies 
when deemed relevant
• Cohorts in which women received 
treatment will be excluded, unless this 
is part of the research question
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For randomized trials:
• Selected women with either subclinical 
hypothyroidism, isolated hypothyrox-
inemia, or thyroid antibodies
• Randomized to treatment or a control 
group consisting either of no treatment 
or placebo
• Follow-up complete until the end of 
pregnancy or beyond
• Disease-specific prospective cohorts 
can be included for specific studies 
when deemed relevant
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